[go: up one dir, main page]

AR057214A1 - Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas. - Google Patents

Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas.

Info

Publication number
AR057214A1
AR057214A1 ARP060105310A ARP060105310A AR057214A1 AR 057214 A1 AR057214 A1 AR 057214A1 AR P060105310 A ARP060105310 A AR P060105310A AR P060105310 A ARP060105310 A AR P060105310A AR 057214 A1 AR057214 A1 AR 057214A1
Authority
AR
Argentina
Prior art keywords
designates
nhet1
het1
oconh
nhcoo
Prior art date
Application number
ARP060105310A
Other languages
English (en)
Inventor
Dieter Dorsch
Oliver Schadt
Andree Blaukat
Dipl-Chem
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR057214A1 publication Critical patent/AR057214A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composiciones farmacéuticas que los contienen, método de preparacion y usos, para el tratamiento de tumores. Reivindicacion 1: Compuestos de la formula (1) en donde R1 designa Ar1 o Het; R2 designa Ar2 o Het; R3 designa H o A; A designa alquilo C1- 10 no ramificado o ramificado, en donde 1-7 átomos de H pueden estar reemplazados por F, Cl y/o Br, y/o en donde uno o dos grupos CH2 pueden estar reemplazados por grupos O, S, SO, SO2 y/o CH=CH; o alquilo C3-7 cíclico; Ar1 designa fenilo, naftilo o bifenilo, cada uno de los cuales no está sustituido o está mono-, di- o trisustituido con Hal, A, OR3, N(R3)2, SR3, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3SO2A, SO2N(R3)2, S(O)mA, CO-Het1, Het1, O[C(R3)2]nN(R3), O[C(R3)2]nHet1, NHCOOA, NHCON(R3)2, NHCOO[C(R3)2]nN(R3)2, NHCOO[C(R3)2]pHet1, NHCONH[C(R3)2]nN(R3)2, NHCONH[C(R3)2]pHet1, OCONH[C(R3)2]nN(R3)2, OCONH[C(R3)2]nHet1, CHO y/o COA; Ar2 designa fenilo, naftilo o bifenilo, cada uno de los cuales está mono-, di- o trisustituido con Hal A, OR3, N(R3)2, SR3, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3SO2A, SO2N(R3)2, S(O)mA, CO-Het1, Het1, O[C(R3)2]nN(R3), O[C(R3)2]nHet1, NHCOOA, NHCON(R3)2, NHCOO[C(R3)2]nN(R3)2, NHCOO[C(R3)2]pHet1, NHCONH[C(R3)2]nN(R3)2, NHCONH[C(R3)2]pHet1, OCONH[C(R3)2]nN(R3)2, OCONH[C(R3)2]nHet1, CHO y/o COA; Het, Het2 designa cada uno, de modo independiente entre sí, un heterociclo saturado, insaturado o aromático mono-, bi- o trisustituido que tiene 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con Hal, A, OR3, (CH2)pN(R3)2, SR3, NO2, CN, COOR3, CON(R3)2, O[C(R3)2]nN(R3), O[C(R3)2]nHet1, NHCOOA, NHCON(R3)2, NHCOO[C(R3)2]nN(R3)2, NHCOO[C(R3)2]nHet1, NHCONH[C(R3)2]nN(R3)2, NHCONH[C(R3)2]nHet1, OCONH[C(R3)2]nN(R3)2, OCONH[C(R3)2]nHet1,NR3COA, NR3SO2A, SO2N(R3)2, S(O)mA, CO-Het1, CHO, COA =S, =NH, =NA, oxi(-O-) y/u =O (oxígeno del carbonilo),; Het1 designa un heterociclo monocíclico saturado o aromático que tiene 1 a 2 átomos de N y/u O, que puede estar mono- o disustituido con A, OA, OH, Hal y/u =O (oxígeno del carbonilo), Hal designa F, Cl, Br o I; m designa 0, 1 o 2; n designa 1, 2, 3 o 4; p designa 0, 1, 2, 3, o 4; y derivados, solvatos, sales, tautomeros y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones.
ARP060105310A 2005-12-05 2006-12-01 Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas. AR057214A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005057924A DE102005057924A1 (de) 2005-12-05 2005-12-05 Pyridazinonderivate

Publications (1)

Publication Number Publication Date
AR057214A1 true AR057214A1 (es) 2007-11-21

Family

ID=37775213

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105310A AR057214A1 (es) 2005-12-05 2006-12-01 Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas.

Country Status (27)

Country Link
US (1) US8173653B2 (es)
EP (1) EP1960370B1 (es)
JP (1) JP5210172B2 (es)
KR (1) KR101367447B1 (es)
CN (1) CN101326167B (es)
AR (1) AR057214A1 (es)
AT (1) ATE527241T1 (es)
AU (1) AU2006322364B2 (es)
BR (1) BRPI0619407A2 (es)
CA (1) CA2632217C (es)
CY (1) CY1112206T1 (es)
DE (1) DE102005057924A1 (es)
DK (1) DK1960370T3 (es)
EA (1) EA014667B1 (es)
EC (1) ECSP088598A (es)
ES (1) ES2373117T3 (es)
IL (1) IL191832A (es)
MY (1) MY153261A (es)
NZ (1) NZ569568A (es)
PE (1) PE20070832A1 (es)
PL (1) PL1960370T3 (es)
PT (1) PT1960370E (es)
SI (1) SI1960370T1 (es)
TW (1) TWI395741B (es)
UA (1) UA95934C2 (es)
WO (1) WO2007065518A1 (es)
ZA (1) ZA200805877B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009000884A (es) 2006-07-25 2009-06-05 Cephalon Inc Derivados de piridizinona.
DE102006037478A1 (de) * 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
CN102442941A (zh) * 2006-12-14 2012-05-09 安斯泰来制药有限公司 用作crth2拮抗剂和抗过敏剂的多环酸化合物
BRPI0809498A2 (pt) * 2007-04-02 2014-09-23 Inst Oneworld Health Compostos inibidores de cftr e seus usos
DE102007025718A1 (de) * 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
DE102007025717A1 (de) 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007038957A1 (de) * 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
DE102007061963A1 (de) * 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
CN101538245B (zh) * 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
MX2011006682A (es) * 2008-12-22 2011-07-13 Merck Patent Gmbh Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirim idin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion.
DE102008062826A1 (de) 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
DE102009003954A1 (de) * 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate
NZ594404A (en) 2009-01-08 2013-04-26 Merck Patent Gmbh Novel polymorphic forms of 3-(1-{ 3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl} -6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
DE102009004061A1 (de) 2009-01-08 2010-07-15 Merck Patent Gmbh Pyridazinonderivate
CN102731409A (zh) * 2011-04-08 2012-10-17 中国科学院上海药物研究所 一类哒嗪酮类化合物，其药物组合物、制备方法及用途
KR101842645B1 (ko) 2012-04-12 2018-03-29 한국화학연구원 신규한 히드라진온이 치환된 피리미딘 유도체 및 그의 용도
JP6255028B2 (ja) * 2012-11-02 2017-12-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 肝細胞癌（ｈｃｃ）の処置のための使用のための６−オキソ−１，６−ジヒドロ−ピリダジン誘導体
LT3057586T (lt) 2013-10-18 2020-03-10 Celgene Quanticel Research, Inc. Bromodomeno inhibitoriai
CN103772352B (zh) * 2014-01-16 2017-01-18 四川百利药业有限责任公司 哒嗪酮类衍生物及其制备方法和用途
CA2970394C (en) * 2014-12-11 2023-03-14 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
CA3041676A1 (en) * 2016-10-26 2018-05-03 Daniel Parks Pyridazine derivatives, compositions and methods for modulating cftr
CN107334767B (zh) * 2017-06-08 2019-03-05 中国医学科学院医药生物技术研究所 一种哒嗪酮类化合物在肿瘤治疗中的应用
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
ES2957383T3 (es) 2018-11-06 2024-01-18 Edgewise Therapeutics Inc Compuestos de piridazinona y usos de estos
EA202191084A1 (ru) 2018-11-06 2021-10-19 Эджвайз Терапьютикс, Инк. Соединения пиридазинонов и их применения
JP7671245B2 (ja) * 2018-11-06 2025-05-01 エッジワイズ セラピューティクス， インコーポレイテッド ピリダジノン化合物およびその使用
EP3935050B1 (en) 2019-03-06 2024-10-02 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO79566A2 (ro) * 1980-05-28 1982-08-17 Institutul De Cercetari Chimico-Farmaceutice,Ro Substante din clasa 2-(3'-aril-piridazonil-1'5-metil-5-aril-(alchil)amino-tiadiazolului
RO79562A2 (ro) * 1980-05-29 1982-08-17 Institutul De Cercetari Chimico-Farmaceutice,Ro Substante din clasa 3-(3'-aril-piridazonil-1'5-metil-4-aril(alchil)-5-mercapto-1,2,4-triazolului si procedeu de obtinere a acestora
JPS5826802A (ja) * 1981-08-10 1983-02-17 Sankyo Co Ltd 農園芸用殺菌剤
DE3321012A1 (de) * 1983-06-10 1984-12-13 A. Nattermann & Cie GmbH, 5000 Köln Substituierte 4,5-dihydro-6-(thien-2-yl)-3(2h)-pyridazinone und 6-(thien-2-yl)-3(2h)-pyridazinone sowie verfahren zu ihrer herstellung
ES2131506T3 (es) 1990-09-21 1999-08-01 Rohm & Haas Dihidropiridacinonas y piridacinonas como fungicidas.
BR9104043A (pt) * 1990-09-21 1992-06-02 Rohm & Haas Composicao fungicida,processo para a producao de compostos di-hidropiridazinona e processo para a preparacao de materias de partida para a producao de compostos
AU691673B2 (en) * 1994-11-14 1998-05-21 Dow Agrosciences Llc Pyridazinones and their use as fungicides
US6121251A (en) * 1996-10-11 2000-09-19 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
WO1999010332A1 (en) * 1997-08-22 1999-03-04 Abbott Laboratories Prostaglandin endoperoxide h synthase biosynthesis inhibitors
MXPA00004955A (es) * 1997-11-19 2002-10-17 Kowa Co Derivados novedosos de piridazina y medicinas que los contienen como ingredientes activos.
US7060822B1 (en) 1999-07-30 2006-06-13 Abbott Gmbh & Co. Kg 2-pyrazolin-5-ones
JP2003506368A (ja) * 1999-07-30 2003-02-18 バスフ アクチエンゲゼルシヤフト ２−ピラゾリン−５−オン
AUPR606401A0 (en) 2001-07-02 2001-07-26 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
CA2462525A1 (en) 2001-10-31 2003-05-08 Merck Patent Gesellschaft Mit Beschraenkter Haftung Type 4 phosphodiesterase inhibitors and uses thereof
MXPA04006781A (es) * 2002-01-18 2004-11-10 Pharmacia Corp Piridazinonas sustituidas con darilo.
WO2004022540A2 (en) * 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Pyridazinone and pyridone derivatives as adenosine antagonists
US7314877B2 (en) * 2003-03-07 2008-01-01 Kowa Co., Ltd. Benzofuran derivative
CN101410120A (zh) 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
MXPA05011294A (es) * 2003-04-25 2006-03-15 Gilead Sciences Inc Compuestos de fosfonato anti-inflamatorios.
JP4890439B2 (ja) 2005-03-07 2012-03-07 杏林製薬株式会社 ピラゾロピリジン−４−イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤

Also Published As

Publication number Publication date
DE102005057924A1 (de) 2007-06-06
IL191832A0 (en) 2008-12-29
AU2006322364A1 (en) 2007-06-14
CA2632217A1 (en) 2007-06-14
CN101326167B (zh) 2011-03-09
ZA200805877B (en) 2009-07-29
JP5210172B2 (ja) 2013-06-12
CY1112206T1 (el) 2015-12-09
UA95934C2 (ru) 2011-09-26
ES2373117T3 (es) 2012-01-31
ECSP088598A (es) 2008-08-29
JP2009518323A (ja) 2009-05-07
PL1960370T3 (pl) 2012-01-31
KR20080077664A (ko) 2008-08-25
ATE527241T1 (de) 2011-10-15
SI1960370T1 (sl) 2011-12-30
EP1960370B1 (de) 2011-10-05
CN101326167A (zh) 2008-12-17
TW200804303A (en) 2008-01-16
DK1960370T3 (da) 2012-01-02
NZ569568A (en) 2011-05-27
PT1960370E (pt) 2012-01-11
PE20070832A1 (es) 2007-08-27
US20080293719A1 (en) 2008-11-27
US8173653B2 (en) 2012-05-08
EP1960370A1 (de) 2008-08-27
MY153261A (en) 2015-01-29
KR101367447B1 (ko) 2014-02-25
IL191832A (en) 2013-09-30
EA200801428A1 (ru) 2008-10-30
WO2007065518A1 (de) 2007-06-14
TWI395741B (zh) 2013-05-11
CA2632217C (en) 2014-07-08
HK1127489A1 (en) 2009-09-25
BRPI0619407A2 (pt) 2011-10-04
EA014667B1 (ru) 2010-12-30
AU2006322364B2 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
AR057214A1 (es) Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas.
AR066770A1 (es) Derivados de piridazinona
AR066769A1 (es) Derivados de arileter-piridazinona
AR066543A1 (es) Derivados de piridazinona
AR071208A1 (es) Derivados de piridazinona
AR069843A1 (es) Derivados de piridazinona, procedimiento para preparar dichos compuestos, composiciones farmaceuticas y usos de los mismos para preparar un medicamento
AR072860A1 (es) Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina
AR076750A1 (es) Derivados de 3-((1,2,3) triazol -4-il)- pirrolo (2,3-b) piridina
AR066892A1 (es) Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit
AR083670A1 (es) DERIVADOS DE 7-([1,2,3]TRIAZOL-4-IL)-PIRROLO[2,3-b]PIRAZINA UTILES COMO INHIBIDORES DE LA PROLIFERACION CELULAR, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y PROCEDIMIENTO PARA PREPARARLOS
AR072192A1 (es) Derivados de tiazolil-piperidina
AR073055A1 (es) Derivados biciclicos de triazol
AR076006A1 (es) Compuestos heterociclicos inhibidores de autotaxina utiles para el tratamiento de tumores, proceso para prepararlos y medicamentos que los contienen.
AR074688A1 (es) Derivados de piridazinona, procedimiento para prepararlos, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores.
AR059488A1 (es) Hidrazidas de acido mandelico
AR075122A1 (es) Derivados de piridazinona
AR068872A1 (es) 5- ciano- tienopiridinas. procesos de obtencion y composiciones farmaceuticas.
AR072792A1 (es) DERIVADOS DE PIRROLOPIRIDINILPIRIMIDIN-2-IL-AMINA, PROCEDIMIENTO DE PREPARACIoN Y COMPOSICIONES FARMACEUTICAS
AR096235A1 (es) Arilquinazolinas
AR055376A1 (es) Derivados de 1-acildihidropirazol
AR067081A1 (es) Derivados de pirrolo[2,3-b]piridin-pirimidina,proceso de preparacion, medicamentos que los contienen y usos de los mismos para el tratamiento de tumores cancerigenos y metastasis tumorales.
AR068657A1 (es) Derivados de piperidina y piperazina
AR074418A1 (es) Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores
AR082722A1 (es) Derivados de pirimidina
AR077567A1 (es) Derivados de aminopiridina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FG Grant, registration